| HOME >> MEDICINE >> TECHNOLOGY |
world treatment patterns and clinical outcomes in patients with cancer
receiving chemotherapy and ESA therapy.
Data on PROCRIT in Managed Care Settings
-- Abstract: Drug Utilization Patterns and Cost Considerations for
Erythropoiesis Stimulating Agents in Cancer Chemotherapy Patients in a
Managed Care Setting
Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY
Publication Number 5157
A retrospective, observational analysis of ESA utilization in more than
4,100 chemotherapy patients using adjudicated medical claims between
2004 and 2006 from seven health plans was conducted to understand
current utilization patterns. The study examined real-world dosing and
drug costs for ESAs (Epoetin alfa and darbepoetin alfa) in cancer
patients receiving chemotherapy.
-- Abstract: Medical Visit Patterns in Cancer Chemotherapy Patients
Receiving Erythropoiesis Stimulating Agents in a Managed Care Setting
Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY
Publication Number 5156
A retrospective analysis of medical claims between January 2004 and
December 2005 using the Integrated Health Care Information Systems
national database and representing more than 35 health plans was
conducted to describe visit patterns and identify the proportion of
medical visits made exclusively for ESA treatment in cancer
chemotherapy patients.
Observational Data from the DOSE Registry
-- Abstract: Hemoglobin Levels Prior To Blood Transfusions In Oncology
Patients Receiving Chemotherapy and Erythropoiesis-Stimulating Agents
(ESAs): Observational Data from the DOSE Registry
Kay Larholt, Sc.D., Abt Associates, Lexington, MA
Publication Number 4019
A retrospective an
'/>"/>
| SOURCE Ortho Biotech Copyright©2007 PR Newswire. All rights reserved |